Zinc finger protein X-linked is overexpressed in colorectal cancer and is associated with poor prognosis

Introduction

Colorectal cancer (CRC) is the third most common type of cancer worldwide, with over 1.4 million new cancer cases and 50,000 mortalities reported in 2013 (1). However, the biological and molecular mechanisms underlying CRC development remain largely unknown.

Zinc finger protein X-linked (ZFX), a zinc finger protein of the Zfy family, is a transcriptional factor encoded on the mammalian X chromosome which is highly conserved in vertebrates. The full-length ZFX protein contains a DNA-binding domain, an acidic transcriptional activation domain and a nuclear localization sequence (2). Previous studies have demonstrated elevated levels of ZFX in pluripotent embryonic and hematopoietic stem cells, which is required for self-renewal ability (3,4). Overexpression of ZFX has also been demonstrated to confer self-renewal capability in hepatocellular carcinoma (5). In addition, previous studies have revealed that ZFX plays a notable role in regulating the transcription of genes necessary for cell proliferation, cell cycle and cell death (6,7). Therefore, it is speculated that ZFX may also be active in cancers and may represent anti-cancer targets. Notably, ZFX is associated with a number of human cancers, including glioblastoma (8,9), breast cancer (10), osteosarcoma (11,12), lung cancer (13,14), gallbladder cancer (15), prostate cancer (16), laryngeal squamous cell carcinoma (17) and gastric cancer (18). Amini et al also identified that ZFX was significantly upregulated in colon cancer tissues and cell lines (19). However, the biological function of ZFX in CRC remains unclear.

In this study, we firstly detected the expression pattern of ZFX in CRC and revealed that the upregulation of ZFX is strongly associated with advanced tumor stage and shorter survival in CRC patients. Next, we explored the potential functions of ZFX in CRC by depletion of ZFX using small interfering RNA (siRNA) and observed that knockdown of ZFX significantly suppressed CRC cell growth and invasion. Using these approaches we aim to elucidate the role of ZFX in the development of CRC and evaluate ZFX as a potential biomarker for the prognosis of CRC.

Materials and methods

Human CRC specimens

A total of 30 CRC specimens were obtained for use in this study from the First Hospital of Jiaxing, China, between January 2013 and May 2014. The study was approved by the ethics committee of the same hospital, and written informed consent was obtained from all participants in accordance with the provisions of the Helsinki Declaration of 1975. One tissue microarray including 90 pairs of CRC and corresponding normal tissues was purchased from BioChip (Shanghai, China).

Primary antibodies

Anti-ZFX antibody was purchased from Sigma-Aldrich (St. Louis, MO, USA) for immunohistochemical analysis and western blot analysis, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA).

Quantitative polymerase chain reaction (qPCR)

Total RNA was extracted from 30 pairs of matched CRC tissues using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA). All tissues were examined histologically and all matched non-tumor tissues were confirmed to be normal. First-strand cDNA was synthesized using the PrimeScript™ RT reagent kit (Takara, Shiga, Japan) according to the manufacturer's instructions. qPCR was performed using an ABI Prism 7900HT sequence detection system (Applied Biosystems Life Technologies, Foster City, CA, USA) with SYBR® Premix Ex Taq™ II (Takara). 18s RNA was used as an internal control. The primer sequences were as follows: ZFX, 5′-GGCAGTCCACAGCAAGAAC-3′ (forward) and 5′-TTGGTATCCGAGAAAGTCAGAAG-3′ (reverse); 18s, 5′-CGGACAGGATTGACAGATTGATAGC-3′ (forward) and 5′-TGCCAGAGTCTCGTTCGTTATCG-3′ (reverse).

Western blot analysis

Total proteins were harvested from tissues or cells, and standard western blot analysis was performed using anti-ZFX and anti-GAPDH antibodies. All primary antibodies were used at a 1:1000 dilution. Peroxidase-conjugated anti-rabbit IgG secondary antibody was purchased from Kangchen Biotechnology (Shanghai, China) and used at a 1:5000 dilution.

Immunohistochemistry (IHC)

IHC was conducted using a standard streptavidin-biotin-peroxidase complex method. Briefly, paraffin-embedded slices were deparaffinized and rehydrated. Endogenous peroxidase was blocked with 0.3% H2O2 for 15 min at room temperature, then the slides were microwaved for antigen retrieval. Following antigen retrieval, the sections were blocked with sheep serum for 30 min at room temperature and then treated with rabbit anti-ZFX (1:300) at 4°C overnight. Samples incubated with phosphate-buffered saline (PBS) were used as negative controls. Immunolabeling was detected using a diaminobenzidine detection kit (Maixin biotechnology, Fuzhou, China).

Cell culture

Human CRC cell lines HCT116 and LoVo were maintained in RPMI-1640 medium (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum and cultured in a humidified incubator at 37°C under 5% CO2.

RNA interference

All siRNAs specifically targeting ZFX were synthesized by GenePharma (Shanghai, China) using the following sequence: 5′-GACGGGUGAUUCUAUACAUTT-3′, 5′-GUCGGAAAUUGAUCCUUGUTT-3′ and 5′-GCAACAGAGUGAGCUUAAATT-3′. The three siRNAs were used as a pool for siRNA transfection. Non-specific siRNAs (GenePharma) were used as a negative control.

Cell proliferation assay

HCT116 or LoVo Cells were seeded in 96-well plates at 5,000 cells/well following transfection. Cell proliferation was evaluated after 24, 48 and 72 h using cell counting kit-8 (Dojindo, Tokyo, Japan) according to the manufacturer's instructions.

Transwell invasion assay

Transwell cell invasion assays were performed using Boyden chambers with filter inserts (pore size, 8 µm) coated with 40 µg Matrigel in 24-well plates. Twenty-four hours after transfection with or without siRNA, cells were harvested, and 100 µl serum-free media containing 2×105 cells was added into the upper chamber, while 600 µl medium with 20% fetal bovine serum was placed in the lower chamber. Following incubation for 24 h, the cells were fixed in 4% formaldehyde and stained with 0.1% crystal violet in PBS for 30 min at room temperature. Cells on the lower side of the filters were counted under light microscopy in ten randomly selected fields of each filter.

Statistical analysis

Data from at least three independent experiments are presented as the means ± standard deviation. Differences between two groups were compared using Student's paired t-test. The expression of ZFX in CRC tissues was analyzed using the χ2 test. P<0.05 was considered to indicate a statistically significant difference.

Results

ZFX is highly expressed in CRC tissues

First, the ZFX expression level was investigated in normal colorectal tissues and CRC tissues by qPCR and western blot analysis. The results suggested that ZFX mRNA was highly expressed in 66.7% of CRC tissues (P=0.0005, Fig. 1A and B). Western blot analysis of 20 paired CRC tissues further confirmed this finding (Fig. 1C and D).

Figure 1. Expression of zinc finger protein X-linked (ZFX) in colorectal cancer (CRC) tissues. (A and B) mRNA expression of ZFX in 30 pairs of CRC tissues and corresponding normal tissues was analyzed by quantitative polymerase chain reaction and revealed that the mRNA expression of ZFX was significantly upregulated in the majority of CRC tissues compared with matched normal tissues. (C and D) Protein expression of ZFX in 20 pairs of CRC tissues and corresponding normal tissues was analyzed by western blot analysis and revealed that the protein expression of ZFX was significantly upregulated in the majority of CRC tissues compared with matched normal tissues.

Next, ZFX expression in 90 paired CRC tissues was analyzed by IHC, which revealed that ZFX was significantly upregulated in CRC tissues compared with the corresponding non-tumor tissues (P<0.001, Fig. 2A and B). As shown in Fig. 2, ZFX was readily detected in the plasma and part of the nuclei of CRC tissues, whereas little or no staining was observed in the normal colorectal tissues.

Figure 2. Immunohistochemistry (IHC) analysis of zinc finger protein X-linked (ZFX) protein expression in 90 pairs of colorectal cancer (CRC) tissues. (A) Representative images of IHC of ZFX in CRC and normal tissues (magnification, x200). (B) Statistics of ZFX protein expression levels in CRC and normal tissues. The level of ZFX protein was estimated according to immunostaining intensity and compared between cancer and normal tissues.

ZFX expression is correlated with severity of CRC

To test whether ZFX expression was correlated with various clinicopathological features of CRC, 90 CRC cases were stratified by ZFX expression as determined by IHC. ZFX upregulation was observed to be significantly associated with larger tumor size (P=0.01), higher pathological stage (P=0.02), depth of invasion (P=0.047), lymph node invasion (P=0.02) and higher American Joint Committee on Cancer (AJCC) stage (P=0.04), as detailed in Table I.

Table I. Correlation of zinc finger protein X-linked expression and clinicopathological characteristics of colorectal cancer.

Table I.

Correlation of zinc finger protein X-linked expression and clinicopathological characteristics of colorectal cancer.

	Patients with low ZFX expression	Patients with high ZFX expression	P-value
Gender
Male	17	31
Female	15	27	0.980
Age, years
<60	8	15
≥60	24	43	0.930
Tumor size, cm
<5	22	24
≥5	10	34	0.010
Pathological stage
I–II	20	21
III–IV	12	37	0.020
Depth of invasion
T1-T2	10	8
T3-T4	22	50	0.047
Lymph node invasion
No	20	21
Yes	12	37	0.020
AJCC stage
1–2	21	25
3–4	11	33	0.040
Distant metastasis
No	31	54
Yes	1	4	0.650

[i] ZFX, zinc finger protein X-linked; AJCC, American Joint Committee on Cancer.

Given that ZFX is highly expressed in CRC tissues and is associated with various clinicopathological features of CRC, we further tested whether ZFX expression was correlated with poor prognosis in CRC patients. As shown in Fig. 3, CRC patients with higher ZFX expression exhibited a significantly shorter survival time (P=0.019). These results strongly suggest that ZFX expression is correlated with poor prognosis in CRC.

Figure 3. Association between zinc finger protein X-linked (ZFX) expression and overall survival in colorectal cancer (CRC) patients. The 90 CRC patients were stratified into ZFX high and ZFX low expression groups according to the immunostaining intensity of ZFX. CRC patients with higher ZFX expression exhibited a significantly shorter survival time (P=0.019).

Knockdown of ZFX suppresses CRC cell proliferation and invasion

As ZFX was significantly upregulated in CRC tissues and associated with the severity of CRC, we next explored its potential function in CRC cells. To test this, specific siRNAs were employed to knock down ZFX expression in the human CRC cell lines HCT116 and LoVo. qPCR and western blot analysis revealed efficient knockdown of ZFX in HCT116 and LoVo cell lines (Fig. 4C and D). The cell counting kit-8 assay was adopted to explore the influence of proliferation by depletion of ZFX and revealed that suppression of ZFX significantly decreased the proliferation rate of HCT116 and LoVo cell lines (Fig. 4A and B). Transwell assay was used to further study the association of ZFX with cell invasion. Knockdown of ZFX significantly decreased the number of penetrated HCT116 and LoVo cells, which suggested a substantial loss of cell invasion ability by depletion of ZFX (Fig. 5A and B).

Figure 4. Knockdown of zinc finger protein X-linked (ZFX) significantly suppressed colorectal cancer (CRC) cell proliferation. Proliferation curves of HCT116 (A) and LoVo (B) cells were determined by cell counting kit-8 assay. Knockdown of ZFX by ZFX siRNA significantly suppressed CRC cell proliferation. Quantitative polymerase chain reaction (C) and western blot analysis (D) revealed efficient knockdown of ZFX in HCT116 and LoVo cell lines.

Figure 5. Knockdown of zinc finger protein X-linked (ZFX) significantly suppressed invasion of colorectal cancer (CRC) cells. HCT116 and LoVo cells were transfected with ZFX siRNAs, and Transwell assay was applied to evaluate cell invasion ability. (A) Statistics of average invasion cells in ZFX short interfering RNA (siRNA) group and control siRNA group in HCT116 and LoVo cells based on three independent experiments; (B) Representative images of invasion cells in ZFX siRNA group and control siRNA group in HCT116 and LoVo cells (magnification, x200).

Discussion

It was reported that zinc finger-containing transcription factors are involved in various physiological functions including differentiation, migration and proliferation, thus contributing to cancer development (20). As ZNF proteins contain an acidic transcriptional activation domain, ZFX may function as a transcription factor which promotes the transcription of growth factors or oncogenes (21). In fact, a number of previous studies have suggested ZFX as a transcriptional regulator and oncogene in various cancer types. As examples, a study by Wu et al demonstrated that knockdown of ZFX inhibited gastric cancer growth by downregulating the ERK-MAPK pathway (18), Yang et al observed that knockdown of ZFX suppressed breast cancer cell proliferation by targeting Akt and ERK2 (10), and Li et al revealed that ZFX knockdown inhibited the growth and migration of lung cancer cells by suppressing MMP-2 and Ki-67 (13). However, the function of ZFX in CRC remains unclear.

By investigating the expression pattern and function of ZFX in the context of CRC, the present study provides evidence that ZFX may function as an oncogene in CRC progression. ZFX was demonstrated to be upregulated in CRC and was associated with tumor size, pathological stage, lymph node invasion, depth of invasion and AJCC stage. More significantly, it was noted that CRC patients with higher ZFX expression levels exhibited a significantly shorter survival time. These clinicopathological findings suggest that ZFX may contribute to the malignant phenotypes of CRC. In cultured CRC cell lines, knockdown of ZFX inhibited CRC cell proliferation and invasion. These results were consistent with previous studies in breast, gastric and lung cancers (10,13,18). The strong correlation between ZFX and CRC tumor size, invasion and AJCC stage highlights the potential value of ZFX as a novel biomarker for CRC.

Previous studies have identified that ZFX regulates the expression and signaling pathway function of various genes, including ERK-MAPK, ERK2, MMP-2, CyclinD1, Stat3, Akt and c-myc. In fact, in these genes, signaling pathways along with certain other pathways, including wnt/β-catenin, play essential roles in CRC progression (22–26). The correlation between ZFX and these genes and pathways in CRC progression requires further study.

In summary, our study confirmed that ZFX was overexpressed in CRC, and was associated with tumor size, lymph node invasion, depth of invasion and overall survival time. Knockdown of ZFX in CRC cell lines inhibited cell proliferation and invasion. These results highlight the potential role of ZFX as a novel biomarker as well as a sensitive therapeutic target for CRC.

Acknowledgements

This study was funded by the Natural Science Foundation of Zhejiang (LY14H60009).

References